145 related articles for article (PubMed ID: 35937307)
1. Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.
Rodler S; Buchner A; Eismann L; Schulz GB; Marcon J; Ledderose S; Schlenker B; Stief CG; Karl A; Jokisch JF
Res Rep Urol; 2022; 14():281-290. PubMed ID: 35937307
[TBL] [Abstract][Full Text] [Related]
2. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.
May M; Bastian PJ; Burger M; Bolenz C; Trojan L; Herrmann E; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Otto W; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Fritsche HM
BJU Int; 2011 Oct; 108(8 Pt 2):E278-83. PubMed ID: 21699644
[TBL] [Abstract][Full Text] [Related]
3. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
[TBL] [Abstract][Full Text] [Related]
4. Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.
von Rundstedt FC; Mata DA; Kryvenko ON; Shah AA; Jhun I; Lerner SP
Bladder Cancer; 2017 Jan; 3(1):35-44. PubMed ID: 28149933
[No Abstract] [Full Text] [Related]
5. Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland.
Nikulainen I; Salminen AP; Seikkula H; Högerman M; Perez IM; Koskinen I; Sairanen J; Nikkola J; Murtola TJ; Vaarala MH; Jousmäki S; Nykopp TK; Isotalo T; Marttila T; Alibeto A; Seppänen M; Palmberg C; Boström PJ
Acta Oncol; 2023 Aug; 62(8):829-835. PubMed ID: 37377029
[TBL] [Abstract][Full Text] [Related]
6. Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
Xia L; Dadabhoy A; Wood EL; Mehta SV; Roberson DS; Guzzo TJ; Bivalacqua TJ; Daneshmand S
Urol Oncol; 2024 May; ():. PubMed ID: 38697874
[TBL] [Abstract][Full Text] [Related]
7. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
8. [Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens].
May M; Fritsche HM; Brookman-May S; Burger M; Bolenz C; Trojan L; Herrmann E; Michel MS; Wülfing C; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Gunia S; Bastian PJ
Urologe A; 2010 Dec; 49(12):1508-15. PubMed ID: 20922515
[TBL] [Abstract][Full Text] [Related]
9. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease.
Tollefson MK; Boorjian SA; Farmer SA; Frank I
World J Urol; 2012 Dec; 30(6):795-9. PubMed ID: 22447397
[TBL] [Abstract][Full Text] [Related]
10. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.
Moschini M; Shariat SF; Abufaraj M; Soria F; Klatte T; Croce G; Mattei A; Damiano R; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
Urol Oncol; 2017 Apr; 35(4):151.e17-151.e23. PubMed ID: 27932269
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
13. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes.
Snow-Lisy DC; Campbell SC; Gill IS; Hernandez AV; Fergany A; Kaouk J; Haber GP
Eur Urol; 2014 Jan; 65(1):193-200. PubMed ID: 24018019
[TBL] [Abstract][Full Text] [Related]
14. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
15. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma.
Evers PD; Logan JE; Sills V; Chin AI
World J Urol; 2014 Apr; 32(2):385-91. PubMed ID: 23756991
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.
Lin J; Whalen M; Holder D; Hruby G; Decastro GJ; McKiernan J
Can J Urol; 2013 Apr; 20(2):6690-5. PubMed ID: 23587508
[TBL] [Abstract][Full Text] [Related]
17. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
18. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.
Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA
World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657
[TBL] [Abstract][Full Text] [Related]
19. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
Tilki D; Svatek RS; Novara G; Seitz M; Godoy G; Karakiewicz PI; Kassouf W; Fradet Y; Fritsche HM; Sonpavde G; Izawa JI; Ficarra V; Lerner SP; Schoenberg M; Stief CG; Dinney CP; Skinner E; Lotan Y; Sagalowsky AI; Reich O; Shariat SF
J Urol; 2010 Sep; 184(3):888-94. PubMed ID: 20643448
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?
Rodler S; Buchner A; Ledderose ST; Eismann L; Volz Y; Pfitzinger P; Kretschmer A; Schulz GB; Karl A; Schlenker B; Stief CG; Jokisch F
World J Urol; 2021 Jul; 39(7):2537-2543. PubMed ID: 33084922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
